Overview on how oncogenic Kras promotes pancreatic carcinogenesis by inducing low intracellular ROS levels.
about
Oxidative Stress and Antioxidant Defense in Endometriosis and Its Malignant TransformationCytoprotection "gone astray": Nrf2 and its role in cancerSoluble factors from stellate cells induce pancreatic cancer cell proliferation via Nrf2-activated metabolic reprogramming and ROS detoxificationHippo signaling pathway in liver and pancreas: the potential drug target for tumor therapy.Erbin is a novel substrate of the Sag-βTrCP E3 ligase that regulates KrasG12D-induced skin tumorigenesisTargeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachoneFunctional annotation of rare gene aberration drivers of pancreatic cancerHypoxia-induced lncRNA-NUTF2P3-001 contributes to tumorigenesis of pancreatic cancer by derepressing the miR-3923/KRAS pathway.KRas, ROS and the initiation of pancreatic cancerPeroxiredoxin I is important for cancer-cell survival in Ras-induced hepatic tumorigenesisKRAS: feeding pancreatic cancer proliferation.Inhibition of glutamine metabolism counteracts pancreatic cancer stem cell features and sensitizes cells to radiotherapy.The role of hypoxia in pancreatic cancer: a potential therapeutic target?Glutamine at focus: versatile roles in cancer.Mutant KRAS associated malic enzyme 1 expression is a predictive marker for radiation therapy response in non-small cell lung cancer.Chemomodulatory efficacy of lycopene on antioxidant enzymes and carcinogen-induced cutaneum carcinoma in mice.The regulatory G4 motif of the Kirsten ras (KRAS) gene is sensitive to guanine oxidation: implications on transcription.Teaching the basics of reactive oxygen species and their relevance to cancer biology: Mitochondrial reactive oxygen species detection, redox signaling, and targeted therapies.The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer.Risk factors for pancreatic cancer: underlying mechanisms and potential targetsNovel Methylselenoesters Induce Programed Cell Death via Entosis in Pancreatic Cancer Cells
P2860
Q26799616-8364EE63-2781-4081-A645-78064DD7AA79Q28393784-4F9D7B76-A5BA-47C7-BF52-D5E25453EE35Q28822225-A079EB58-3608-4A23-B289-AB2B196AD671Q35484837-507FA1CC-99E0-4FEF-947D-45F63F0746BEQ35697259-76158C40-94C0-49C3-9089-363CDE16009BQ36146939-5C1C9E7E-642D-42D0-9739-9FFF74B3190BQ36534290-66E714E9-2800-4DA6-BF5F-51B764E8CA34Q36905828-18C18E32-3F34-4A84-A105-14097E786F8EQ37673906-85A23E36-C55F-45F4-A487-605D667EDE29Q37708749-75EB5246-04EB-4FFC-9001-7E9AABE8AA4DQ38175666-2C18D50A-2DDA-4793-AF23-DAF2C00BD028Q38260557-E3FC3E7B-42FE-409F-B8B7-3D4C06179E4BQ38631404-D645FF6B-56B8-4287-8262-15E4273D222EQ38678184-55EAC7A5-096E-40A9-B181-8F72D0F32E66Q38853126-D9E7226E-CA26-41F9-8158-5A551F5FFDE9Q46899918-BB854FC3-885B-4516-9B9D-6DF01161138DQ47373966-55030149-0D2A-4D3A-BD1B-11AD2DA3AF2DQ49182137-F719508F-A2DF-4B65-9456-F1DE84689472Q55252442-6F96A336-6A87-4780-9EA0-53950CD0654AQ58563303-E54BB954-FEFD-4E34-9F2D-359580DF2FD0Q59133924-388C399B-7AB3-49EB-92FE-C9957C4552A9
P2860
Overview on how oncogenic Kras promotes pancreatic carcinogenesis by inducing low intracellular ROS levels.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Overview on how oncogenic Kras ...... low intracellular ROS levels.
@en
Overview on how oncogenic Kras ...... low intracellular ROS levels.
@nl
type
label
Overview on how oncogenic Kras ...... low intracellular ROS levels.
@en
Overview on how oncogenic Kras ...... low intracellular ROS levels.
@nl
prefLabel
Overview on how oncogenic Kras ...... low intracellular ROS levels.
@en
Overview on how oncogenic Kras ...... low intracellular ROS levels.
@nl
P2093
P2860
P356
P1476
Overview on how oncogenic Kras ...... low intracellular ROS levels.
@en
P2093
Chengjia Qia
Christoph W Michalski
Jörg Kleeff
P2860
P356
10.3389/FPHYS.2013.00246
P50
P577
2013-09-12T00:00:00Z